Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Vergne

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype BBrigitte Montes, Laurence Vergne, Martine Peeters, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 28, 2006
Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patientsLaurence Vergne, Lieven Stuyver, Margriet Van Houtte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countriesLaurence Vergne, Gabriel Malonga-Mouellet, Irene Mistoul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and JCeline Montavon, Coumba Toure-Kane, John N Nkengasong, et al.
FEMS Immunology and Medical Microbiology|January 20, 2006
Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patientsLaurence Vergne, Joke Snoeck, Avelin Aghokeng, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J, and CRF01-AE, in Central AfricaCeline Montavon, Laurence Vergne, Anke Bourgeois, et al.
Virology|June 5, 2003
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stageLaurence Vergne, Anke Bourgeois, Eitel Mpoudi-Ngole, et al.
Emerging Infectious Diseases|May 19, 2006
Antiretroviral drug resistance and routine therapy, CameroonChristian Laurent, Charles Kouanfack, Laurence Vergne, et al.
AIDS (London, England)|April 7, 2007
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudineChristian Laurent, Charles Kouanfack, Sinata Koulla-Shiro, et al.
Journal of Clinical Microbiology|March 7, 2002
Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AGJean-Christophe Plantier, Laurence Vergne, Florence Damond, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype BBrigitte Montes, Laurence Vergne, Martine Peeters, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 28, 2006
Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patientsLaurence Vergne, Lieven Stuyver, Margriet Van Houtte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countriesLaurence Vergne, Gabriel Malonga-Mouellet, Irene Mistoul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and JCeline Montavon, Coumba Toure-Kane, John N Nkengasong, et al.
FEMS Immunology and Medical Microbiology|January 20, 2006
Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patientsLaurence Vergne, Joke Snoeck, Avelin Aghokeng, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J, and CRF01-AE, in Central AfricaCeline Montavon, Laurence Vergne, Anke Bourgeois, et al.
Virology|June 5, 2003
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stageLaurence Vergne, Anke Bourgeois, Eitel Mpoudi-Ngole, et al.
Emerging Infectious Diseases|May 19, 2006
Antiretroviral drug resistance and routine therapy, CameroonChristian Laurent, Charles Kouanfack, Laurence Vergne, et al.
AIDS (London, England)|April 7, 2007
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudineChristian Laurent, Charles Kouanfack, Sinata Koulla-Shiro, et al.
Journal of Clinical Microbiology|March 7, 2002
Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AGJean-Christophe Plantier, Laurence Vergne, Florence Damond, et al.
Pageof 2